Main Line synthetic cannabinoid developer seeking $32.5M from stock sale

Zynerba Pharmaceuticals Inc., a specialty pharmaceutical company developing synthetic cannabinoid-based therapies, is looking to raise $32.5 million through a public stock offering. The Devon, Pa., company plans to sell nearly 4.1 million shares of its common stock at $8 per share. The pricing is below Zynerba's 2015 initial public offering of price of $14 per share. The public offering is expected to close on or about July 24. The company has granted underwriters the option to purchase an additional…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news